Several individual stocks made notable moves in early trading, driven by analyst upgrades, a major partnership announcement, and a significant pharmaceutical acquisition. The themes connecting these moves are the ongoing artificial intelligence infrastructure buildout and consolidation in the pharmaceutical industry.
Micron: Bullish Momentum Ahead of Earnings
Micron is a key name to watch, with earnings due Wednesday after the close. In what is otherwise a relatively earnings-light week, this report is positioned as a major focus item. Analysts have been increasingly bullish, with several continuing to update their price targets following the bullish momentum from the sell side seen in the previous week. Some observers would characterize this wave of upgrades as analysts "playing catchup" relative to where the shares already sit.
One of the most aggressive moves came from a firm boosting its price target all the way up to $550, raised from $500 — now one of the most aggressive targets on Wall Street for the stock. The shares were rallying roughly 5% on the day, adding to the momentum already seen throughout the year.
The scale of Micron's run is striking. The year began with shares around $285 by the end of the prior year, and they now sit near $1,098 (referenced as "98" in the high triple-digit range), representing a gain of more than 300% on the year and more than 800% higher on a year-over-year basis.
AI is the central driver of the story. The bullish thesis frames this as a demand story combined with a pricing story — Micron is raising prices, and there is only limited new capacity coming online. One market commentator from a financial services firm questioned where these analysts had been, arguing that Micron is still cheap. A key point supporting this view is the unusual degree of visibility: Micron and other names in the memory space reportedly have visibility extending out eight quarters, which was described as atypical and not the norm for the industry.
A major catalyst is a newly announced strategic agreement between Micron and Anthropic. This agreement spans memory and storage, AI architecture design, supply and demand, and enterprise adoption of Claude. It is aligned with Anthropic's funding for agentic AI initiatives, linking the demand picture for AI and memory together between the two companies. The momentum around Micron also pulled along related names, including Western Digital and SanDisk, which posted gains as well.
Credo: An Emerging AI Infrastructure Play
Credo (CRDO) made a substantial move, with shares up almost 7% out of the gate. The stock benefited from a wave of analyst coverage. Stifel maintained a buy rating while raising its price target to $350. The momentum was actually started by Evercore ISI, which initiated coverage with an outperform rating — essentially the equivalent of a buy — and set a $325 price target, signaling double-digit upside from recent levels.
The core view is that investors are still underestimating Credo's role in the AI infrastructure buildout. The company has been in focus primarily because of its leadership in copper-based connectivity. While copper remains attractive, Evercore's argument is that the company is no longer just a copper story. Credo is expanding into optical technology, which is expected to open up more growth opportunities going forward.
Credo sits in the "picks and shovels" category of the AI infrastructure buildout — the area that has been a focus this year, particularly given the momentum in the memory space. The relevant question is which companies represent the next level of runners in the AI buildout story, and Credo is identified as one of those names. Evercore believes the company's future optical products could significantly expand its market opportunity. The advanced technologies in development include optical processors, silicon photonics, and advanced optical modules. The shares are now up more than 100% on the year.
AbbVie Acquires Apogee Therapeutics
AbbVie (ABBV) is seeing deal-driven movement after announcing an acquisition valued at nearly $11 billion to boost its core immunology franchise. This fits a broader trend of consolidation in the pharmaceutical space seen throughout the year, a trend that appears to be continuing. Much of this consolidation is driven by drugs facing a patent cliff, which is expected to prompt further deal-making across the industry as companies look to fill their pipelines.
Notably, the shares of the acquirer moved higher — an unusual reaction, since acquirers typically do not rise on deal news. This clearly signals that the market likes the deal. AbbVie shares rose about 5%, while Apogee shares jumped more than 40% (about 46% higher) on the news.
AbbVie agreed to buy Apogee Therapeutics for almost $11 billion, just above $135 per share, with the deal expected to close in the third quarter of the year. The acquisition gives AbbVie access to Apogee's lead experimental drugs, which are potential treatments for inflammatory conditions including eczema and asthma. The strategic goal is to strengthen AbbVie's immunology business, especially in light of the patent expirations the company faces. The acquired treatments would compete with blockbuster therapies such as Dupixent and serve as an alternative to other established options. The deal reinforces the broader pattern: as pharmaceutical companies confront patent cliffs and expirations, they are looking to fill their pipelines through acquisition, and investors appear to favor this particular move.
